LY335979

Known as: LY 335979 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1996-2016
024619962016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2009
Highly Cited
2009
The novel tyrosine kinase inhibitor dasatinib (Sprycel; BMS-354825) is approved for use in imatinib (Gleevec; STI 571)-resistant… (More)
  • figure 2
  • figure 1
  • table 1
  • table 2
  • figure 3
Is this relevant?
2009
2009
To determine if concomitant administration of docetaxel plus zosuquidar.3HC1 can prolong progression-free survival in patients… (More)
  • figure 1
  • table 1
Is this relevant?
2007
2007
A phase I/II trial was performed to investigate the safety and tolerance of zosuquidar.3HCL, a potent inhibitor of P-glycoprotein… (More)
Is this relevant?
2003
2003
Our study examines the ability of LY335979 (Zosuquidar trihydrochloride) to modulate 3 distinct ABC transporters that are… (More)
Is this relevant?
Highly Cited
2003
Highly Cited
2003
The adequate distribution of STI-571 (Gleevec) to the central nervous system (CNS) is critical for its effective use in CNS… (More)
  • figure 1
  • figure 2
  • figure 4
  • figure 3
  • figure 5
Is this relevant?
2003
2003
We determined the effect of zosuquidar·3HCl, an inhibitor of P-gp, on the penetration of the anticancer drug paclitaxel into the… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
2001
2001
Resistance to chemotherapy by some human tumors may be due to overexpression of membrane-associated transport proteins. The best… (More)
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Overexpression of ATP-dependent drug efflux pumps, P-glycoprotein (Pgp) or multidrug resistance-associated protein (MRP), confers… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
1997
1997
The above data indicate that LY335979 displays the following characteristics of an 'ideal modulator' of Pgp-mediated multidrug… (More)
Is this relevant?
Highly Cited
1996
Highly Cited
1996
Overexpression of P-glycoprotein (Pgp) by tumors results in multidrug resistance (MDR) to structurally unrelated oncolytics. MDR… (More)
Is this relevant?